Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin

被引：0
|
作者：
Lip, G. Y. H. [1 ]
Pan, X. [2 ]
Kamble, S. [2 ]
Kawabata, H. [2 ]
Mardekian, J. [3 ]
Masseria, C. [3 ]
Bruno, A. [2 ]
Phatak, H. [2 ]
机构：
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Bristol Myers Squibb Co, Princeton, NJ USA
[3] Pfizer Inc, New York, NY USA
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6217
引用
收藏
页码：1085 / 1085
页数：1
相关论文
共 50 条
  • [11] Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Lip, G. Y. H.
    Keshishian, A.
    Kamble, S.
    Pan, X.
    Burns, L.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 501
  • [12] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [13] Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin
    Lin, Iris
    Horblyuk, Ruslan
    Mardekian, Jack
    Park, Sang Hee
    Kamble, Shital
    Hamilton, Melissa
    Abdulsattar, Younos
    Petkun, William
    Menzin, Joseph
    Lip, Gregory Y.
    CIRCULATION, 2016, 134
  • [14] Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    PLOS ONE, 2018, 13 (04):
  • [15] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin
    Tepper, P.
    Mardekian, J.
    Masseria, C.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 339 - 339
  • [16] Real world comparison of major bleeding risk among nonvalvular atrial fibrillation patients newly initiated on apixaban, warfarin, dabigatran or rivaroxaban: a 1:1 propensity-score matched analysis
    Lip, Gregory
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Burns, Leah
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    PHARMACOTHERAPY, 2016, 36 (12): : E213 - E213
  • [17] Contemporary results from EHR study of real-world bleeding risk among elderly and overall non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban and warfarin
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Park, S.
    Horblyuk, R.
    Kamble, S.
    Hamilton, M.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 235 - 236
  • [18] Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Tu, Hui-Tzu
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    See, Lai-Chu
    ONCOTARGET, 2017, 8 (58) : 98898 - 98917
  • [19] REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Qisu, Zhang
    Baser, Onur
    Vo, Lien
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 439 - 439
  • [20] Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
    Alpesh, Amin N.
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Singh, Prianka
    Bruno, Amanda
    Mardekian, Jack
    Tan, Wilson
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    BLOOD, 2015, 126 (23)
12345